BR0202767A - Sistema de aplicação de droga bioadesivo - Google Patents

Sistema de aplicação de droga bioadesivo

Info

Publication number
BR0202767A
BR0202767A BR0202767-4A BR0202767A BR0202767A BR 0202767 A BR0202767 A BR 0202767A BR 0202767 A BR0202767 A BR 0202767A BR 0202767 A BR0202767 A BR 0202767A
Authority
BR
Brazil
Prior art keywords
delivery system
drug delivery
vaginal
therapeutically active
phase
Prior art date
Application number
BR0202767-4A
Other languages
English (en)
Inventor
Mitchell I Kirschner
R Saul Levinson
Thomas C Riley
Marc S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22282669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0202767(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of BR0202767A publication Critical patent/BR0202767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"SISTEMA DE APLICAçãO DE DROGA BIOADESIVO". A presente invenção retere-se a um novo sistema de aplicação de droga vaginal de pH essencialmente neutro adequado para aplicação modificada de material terapeuticamente ativo na cavidade vaginal, o qual otimiza as chances para cura associada ao material terapeuticamente ativo. O sistema de aplicação de droga vaginal compreende uma emulsão de pH essencialmente neutro tendo glóbulos tendo duas fases, uma fase solúvel em água interna e uma fase insolúvel em água externa ou película, onde a fase interior solúvel em água contém uma droga ou drogas terapeuticamente ativa. Um novo aspecto do sistema de aplicação de droga: vaginal e que a fase solúvel em água interna compreende uma fase tamponada ácida.
BR0202767-4A 2002-03-20 2002-07-18 Sistema de aplicação de droga bioadesivo BR0202767A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/101,014 US6899890B2 (en) 2002-03-20 2002-03-20 Bioadhesive drug delivery system

Publications (1)

Publication Number Publication Date
BR0202767A true BR0202767A (pt) 2004-05-25

Family

ID=22282669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202767-4A BR0202767A (pt) 2002-03-20 2002-07-18 Sistema de aplicação de droga bioadesivo

Country Status (17)

Country Link
US (1) US6899890B2 (pt)
EP (1) EP1494630A4 (pt)
JP (1) JP4462818B2 (pt)
KR (2) KR20030076159A (pt)
CN (3) CN101045034A (pt)
AR (1) AR039037A1 (pt)
AU (2) AU2002300175B2 (pt)
BR (1) BR0202767A (pt)
CA (1) CA2392473C (pt)
FR (1) FR2837389A1 (pt)
HU (1) HUP0203102A3 (pt)
IT (1) ITMI20021660A1 (pt)
MX (1) MXPA02006943A (pt)
PT (1) PT102854B (pt)
RU (1) RU2320322C2 (pt)
WO (1) WO2003079981A2 (pt)
ZA (1) ZA200407535B (pt)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
WO2004105662A1 (en) * 2003-05-23 2004-12-09 Program For Appropriate Technology In Health Microbicidal compositions and methods of use
ITTO20030404A1 (it) * 2003-05-30 2004-11-30 Rottapharm S R L Composizione per il ripristino dell'ecosistema vaginale
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
CN1852690B (zh) 2003-09-19 2010-04-14 制药技术有限公司 药物输送系统
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
CA2547990C (en) 2003-12-08 2011-08-02 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US8057433B2 (en) 2004-07-08 2011-11-15 Drugtech Corporation Delivery system
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
ATE540684T1 (de) 2005-04-27 2012-01-15 Shenzhen Phlora Biotechnology Ltd Zubereitung und verfahren zur regulierung und aufrechterhaltung der vaginalen bakterienflora und der normalen acidität in der vagina
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
AU2006244260A1 (en) * 2005-05-09 2006-11-16 Drugtech Corporation Modified-release pharmaceutical compositions
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
EP1933810B1 (en) * 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
PE20070329A1 (es) * 2005-08-12 2007-03-29 Drugtech Corp Composiciones con estrogenos y metodos terapeuticos para su uso
JP2009522362A (ja) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション 薬物送達システム
WO2007079389A2 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Composition and method of use thereof
MX2008010350A (es) * 2006-02-09 2008-10-31 Schering Corp Formulaciones farmaceuticas.
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
US20080003262A1 (en) * 2006-06-30 2008-01-03 Drugtech Corporation Compositions and therapeutic methods of use
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080268022A1 (en) * 2007-02-23 2008-10-30 Mccabe R Tyler Mehtods for treating and preventing ailments caused by human papillomavirus
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
EP1994938A1 (en) * 2007-05-21 2008-11-26 Combinature Biopharm AG New lipoglycodepsipeptide compositions
EP2231254B9 (en) 2007-12-11 2015-04-08 Massachusetts Institute of Technology Implantable drug delivery device
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
BRPI0917135A2 (pt) 2008-08-09 2015-11-10 Massachusetts Inst Technology dispositivo médico para extensão e retenção em uma vesícula seminal, duto ejaculatório, próstata ou vaso deferente de um paciente, uso de um elastômero reabsorvível, e, dispositivo de bomba osmótica.
WO2010097344A1 (en) * 2009-02-26 2010-09-02 Basf Se Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
EA023921B1 (ru) 2009-06-26 2016-07-29 ТАРИС Биомедикал ЛЛК Твердые таблетки лекарства для имплантируемых устройств для доставки лекарств
US20110008469A1 (en) * 2009-07-09 2011-01-13 Florida Gulf Coast University Antimicrobial composition and methods and apparatus for use thereof
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
RU2479305C2 (ru) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения инфекционных воспалительных заболеваний в гинекологии и способ ее получения
CA2823783C (en) 2011-01-10 2023-03-21 Taris Biomedical, Inc. Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
WO2012106714A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
CN103442692B (zh) 2011-04-04 2016-05-18 环绕护肤(私人)有限公司 病毒性感染的治疗
CN103596556A (zh) 2011-05-02 2014-02-19 阿普塔利斯医药科技公司 用于阴道给药的快速溶解片剂组合物
KR20140064950A (ko) * 2011-09-19 2014-05-28 옴니액티브 헬스 테크놀로지스 리미티드 올레오레신을 포함하는 라이코펜의 효율적인 제조방법 및 인간 소비용의 라이코펜 결정
US9180094B2 (en) 2011-10-12 2015-11-10 The Texas A&M University System High porosity materials, scaffolds, and method of making
KR101811917B1 (ko) * 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 점액 침투 강화를 나타내는 나노 입자 제형
WO2014018075A1 (en) 2012-07-23 2014-01-30 Crayola, Llc Dissolvable films and methods of using the same
RU2538703C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения
CA2903164A1 (en) 2013-03-15 2014-09-18 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
WO2014192791A1 (ja) * 2013-05-30 2014-12-04 大正製薬株式会社 坐剤
SG10202004675QA (en) 2013-08-19 2020-06-29 Taris Biomedical Llc Multi-unit drug delivery devices and methods
WO2015070074A2 (en) 2013-11-08 2015-05-14 The Texas A &M University System Porous microparticles with high loading efficiencies
US20150238549A1 (en) * 2014-02-27 2015-08-27 Mak Wood, Inc. Probiotic dosage units
EP3113824B1 (en) 2014-03-03 2021-04-14 Cook Medical Technologies LLC Mechanical dilator
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
JP7425534B2 (ja) 2015-04-23 2024-01-31 タリス バイオメディカル エルエルシー 薬物透過性構成要素を有する薬物送達デバイス及び方法
BR112017025392A2 (pt) 2015-05-29 2018-08-07 Eve Pharma Ltd composições vaginais dependentes de ph e métodos de tratamento de distúrbios vaginais
EP3355893A4 (en) 2015-09-29 2019-06-12 Kimberly-Clark Worldwide, Inc. SYNERGISTIC COMPOSITION FOR MAINTAINING A HEALTHY BALANCE OF THE MICROFLORE
KR101880179B1 (ko) * 2016-11-03 2018-07-20 한국생명공학연구원 미카펀진(micafungin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항바이러스용 약학적 조성물
BR112019011015A2 (pt) * 2016-11-30 2019-10-08 Probioswiss Ag uso de uma composição, formulação e seu uso, lubrificante vaginal prebiótico e uso de uma cápsula vaginal simbiótica
US20220047651A1 (en) * 2018-12-19 2022-02-17 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988508A (en) * 1973-03-08 1976-10-26 Petrolite Corporation High internal phase ratio emulsion polymers
DE3321043A1 (de) * 1983-06-10 1984-12-13 Bayer Ag, 5090 Leverkusen Antimykotische mittel fuer einmalige gynaekologische behandlung
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) * 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5055303A (en) * 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5298246A (en) * 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
ATE154241T1 (de) * 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
US5189070A (en) * 1992-05-29 1993-02-23 Shell Oil Company Process for preparing low density porous crosslinked polymeric materials
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5470885A (en) * 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5980936A (en) * 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
CA2306837C (en) * 1997-10-28 2007-05-08 Asivi, Llc. Treatment of female sexual dysfunction
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Also Published As

Publication number Publication date
CA2392473A1 (en) 2003-09-20
US6899890B2 (en) 2005-05-31
PT102854B (pt) 2004-02-27
HUP0203102A3 (en) 2004-06-28
US20030180366A1 (en) 2003-09-25
JP2003286193A (ja) 2003-10-07
CA2392473C (en) 2007-09-18
CN101045034A (zh) 2007-10-03
ITMI20021660A1 (it) 2004-01-26
ZA200407535B (en) 2006-06-28
AU2003218233A8 (en) 2003-10-08
HU0203102D0 (pt) 2002-11-28
JP4462818B2 (ja) 2010-05-12
EP1494630A4 (en) 2007-03-14
AU2003218233A1 (en) 2003-10-08
AU2002300175B2 (en) 2004-04-22
WO2003079981A2 (en) 2003-10-02
RU2320322C2 (ru) 2008-03-27
PT102854A (pt) 2003-09-30
RU2004130870A (ru) 2005-06-10
MXPA02006943A (es) 2004-12-13
AR039037A1 (es) 2005-02-02
CN102048689A (zh) 2011-05-11
KR20030076159A (ko) 2003-09-26
CN1444926A (zh) 2003-10-01
EP1494630A2 (en) 2005-01-12
AU2002300175A1 (en) 2003-10-09
WO2003079981A3 (en) 2003-11-06
KR20080098576A (ko) 2008-11-11
HUP0203102A2 (hu) 2004-05-28
FR2837389A1 (fr) 2003-09-26

Similar Documents

Publication Publication Date Title
BR0202767A (pt) Sistema de aplicação de droga bioadesivo
CA2105529C (en) Composition comprising non-steroidal anti-inflammatory agent and effectively non-antibacterial tetracycline
BR0207614A (pt) Preparação medicinal aderente à mucosa uso de uma preparação aderente à mucosa e processo para ministração de uma subst ncia farmaceuticamente ativa
BR0306513A (pt) tampão com medicamento
BR9910066A (pt) Composição farmacêutica fluida que permite a liberação controlada de pelo menos uma substância ativa, processo de fabricação de uma composição farmacêutica, e, utilização de uma composição
BR0008058A (pt) Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
BRPI0409345A (pt) sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
CY1105816T1 (el) Χρηση θepαπειας με νευροτοξινη για την αντιμετωπιση της κατακρατησης ουρων
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
BR9807234A (pt) Composição farmacêutica
BR0110914A (pt) Composição farmacêutica lìquida, conjugado, processo para preparação e utilização de uma composição, processo para o tratamento e prevenção de enfermidades que envolvem anemia e dispositivo para liberação local e sistêmica sustentada de uma composicão
BR0009770A (pt) Derivados de bisindóis indigóides capazes de penetrarem na membrana de células, formulação farmacêutica e utilização da mesma
BR9914367A (pt) Composições contendo ácidos difosfÈnicos
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BR0013222A (pt) Medicamento para aplicação tópica, uso de um xanteno halogenado, composição farmacêutica para administração tópica, e, método de tratamento
BR0211008A (pt) Combinação de ingrediente ativo, uso de uma combinação de ingrediente ativo e método para a terapia farmacológia de uma substância que causa dependência ou que seja intoxicante
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
BRPI0411832A (pt) forma de administração em forma de pelìcula para a administração transmucosa de substáncias ativas, uso da forma de administração e processo para a produção de uma forma de administração
BR0013252A (pt) Micofenolato mofetila em associação com peg-ifn-alfa
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
EA200501223A1 (ru) Терапевтическая система, содержащая амоксициллин и клавулановую кислоту
TW201924672A (zh) 使用大麻素之抗細菌治療

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.